acute coronary syndrome

AHA 2021 | RAPID CABG: seguridad de ir al quirófano precozmente en un síndrome coronario agudo

AHA 2021 | RAPID CABG: Safety of Early Surgical Intervention in Acute Coronary Syndrome

Suspending ticagrelor a couple of days before surgery was non-inferior to waiting 5-6 days in terms of bleeding in patients with acute coronary syndrome (ACS) requiring myocardial revascularization surgery. Patients who waited longer had more ischemic events and longer hospitalizations. Current American guidelines recommend waiting at least 5&nbsp;days before operating on patients with ACS who<a href="https://solaci.org/en/2021/11/23/aha-2021-rapid-cabg-safety-of-early-surgical-intervention-in-acute-coronary-syndrome/" title="Read more" >...</a>

infarto peri-procedimiento

Post TAVR Acute Coronary Syndrome: Frequency and Potential Damage

After Transcatheter Aortic Valve Replacement (TAVR) acute coronary syndromes (ACS) are rare and mostly present as non-ST elevation events. In this context, the few ST elevation events have bad prognosis, with close to 30% mortality at 30 days.&nbsp; This study included patients undergoing TAVR between 2012 and 2017 admitted for acute coronary syndrome during followup.&nbsp;<a href="https://solaci.org/en/2021/06/22/post-tavr-acute-coronary-syndrome-frequency-and-potential-damage/" title="Read more" >...</a>

Actualización en el tratamiento de síndromes coronarios agudos sin supradesnivel del ST

18/05 | Update on the treatment of acute coronary syndromes without ST segment elevation

Another virtual event open to the whole community! At SOLACI we want to continue promoting continuous medical education and, in that sense, to expand the development of interventional cardiology in Latin America. For this reason, we bring you a new educational proposal, this time an Update on the treatment of acute coronary syndromes without ST<a href="https://solaci.org/en/2021/05/11/18-05-update-on-the-treatment-of-acute-coronary-syndromes-without-st-segment-elevation/" title="Read more" >...</a>

Doctor con tabletas de aspirinas

How To De-Escalate Prasugrel After Acute Coronary Syndrome?

Patients who undergo coronary angioplasty after acute coronary syndrome could de-escalate dual antiplatelet therapy with prasugrel to maintain the protection against ischemic events while lowering their hemorrhagic risk. The HOST-REDUCE-POLYTECH-ACS study (recently published in The Lancet) included 2338&nbsp;patients who underwent coronary angioplasty in a setting of acute coronary syndrome. Patients were randomized to a year-long<a href="https://solaci.org/en/2020/10/21/how-to-de-escalate-prasugrel-after-acute-coronary-syndrome/" title="Read more" >...</a>

ESC 2020 | New European Guidelines on Non-ST-Segment Elevation Acute Coronary Syndromes: What’s New?

The new European guidelines on NON-ST-segment elevation acute coronary syndromes (NSTE ACS) were presented virtually during the European Society of Cardiology 2020 Congress (ESC&nbsp;2020) and published in Eur Heart J. This document includes news regarding a more agile infarction diagnosis, the use of non-invasive imaging, the simplification of anticoagulant therapy, infarction with normal coronary arteries,<a href="https://solaci.org/en/2020/09/11/esc-2020-new-european-guidelines-on-non-st-segment-elevation-acute-coronary-syndromes-whats-new/" title="Read more" >...</a>

Top